PARK2 polymorphisms predict disease progression in patients infected with hepatitis C virus
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 6
Abstract
Background. The protein encoded by PARK2 gene is a component of the ubiquitin-proteasome system that mediates targeting of proteins for the degradation pathway. Genetic variations at PARK2 gene were linked to various diseases including leprosy, typhoid and cancer. The present study investigated the association of single nucleotide polymorphisms (SNPs) in the PARK2 gene with the development of hepatitis C virus (HCV) infection and its progression to severe liver diseases. Material and methods. A total of 800 subjects, including 400 normal healthy subjects and 400 HCV-infected patients, were analyzed in this study. The patients were classified as chronic HCV patients (group I), patients with cirrhosis (group II) and patients with hepatocellular carcinoma (HCC) in the context of cirrhosis (group III). DNA was extracted and was genotyped for the SNPs rs10945859, rs2803085, rs2276201 and rs1931223. Results. Among these SNPs, CT genotype of rs10945859 was found to have a significant association towards the clinical progression of chronic HCV infection to cirrhosis alone (OR = 1.850; 95% C. I. 1.115-3.069; p = 0.016) or cirrhosis and HCC (OR = 1.768; 95% C. I. 1.090-2.867; p value = 0.020). Conclusion. SNP rs10945859 in the PARK2 gene could prove useful in predicting the clinical outcome in HCV-infected patients.
Authors and Affiliations
Mashael Al-Anazi, Ahmed Al-Qahtani, Fahad Al-Zoghaibi, Ayman Abdo, Faisal Sanai, Waleed Al-Hamoudi, Khalid Alswat, Hamad Al-Ashgar, Mohammed Khan, Ali Albenmousa, Hanif Khalak, Mohammed Al-Ahdal
Keywords
Related Articles
- EP ID EP207220
- DOI -
- Views 112
- Downloads 0
Hepatitis E virus exposure in pregnant women in rural Durango, Mexico
Background and Aim. Hepatitis E virus (HEV) infection represents a risk for mortality in pregnant women. The seroepidemiology of HEV infection in rural pregnant women in the Americas is largely unknown. The aim of the st...
On the cusp of change: New therapeutic modalities for HCV
We are at the cusp of significant new alternatives for the treatment of chronic hepatitis C. Among more than 100 drugs in development, some are ready to be approved and in the market as soon as next year. The protease in...
Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience
Introduction and aim. Sofosbuvir (SOF)-based regimen has been shown to have high efficacy even in patients with decompensated cirrhosis. Treated patients may experience various degrees of hepatic recovery ranging from st...
Acute Variceal Bleeding: Does Octreotide Improve Outcomes in Patients with Different Functional Hepatic Reserve?
Background. Current guidelines do not differentiate in the utilization of vasoactive drugs in patients with cirrhosis and acute variceal bleeding (AVB) depending on liver disease severity. Material and methods. In this r...
Unusual cause of common bile duct dilatation in asymptomatic elderly patient: right hepatic artery syndrome